

Special Issue

Novel Approaches to Enhance the Discovery and Efficacy of Antibiotics and Antifungals

Message from the Guest Editor

Antimicrobial resistance (AMR) among bacterial and fungal pathogens presents an uphill battle for clinicians treating infectious diseases. WHO has declared AMR a serious global health threat and has recently underscored that the existing pipeline of antibiotics falls short in addressing AMR. Thus, novel approaches to address AMR are warranted. This Special Issue welcomes all submissions related to unique strategies to counteract AMR, with a special focus on the following areas:

- Discovery and identification of novel antimicrobials or applications of antimicrobial peptides or naturally-derived bioactives;
- Fresh high throughput screens of existing drug and compound libraries to identify novel antimicrobial uses for existing molecules;
- Modulation of host factors (such as iron levels) that can alter antimicrobial sensitivities to existing antimicrobials during infection;
- Identifying and repurposing existing FDA-approved drugs with antimicrobial potential;
- Synergistic approaches between different antimicrobials or non-antimicrobial drugs that can enhance the microbicidal potential of existing antibiotics and antifungals

Guest Editor

Dr. Sumant Puri

Oral Microbiome Research Laboratory, Department of Oral Health Sciences, Kornberg School of Dentistry, Temple University, Philadelphia, PA, USA

Deadline for manuscript submissions

closed (28 February 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/73902

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)